BriaCell Therapeutics Corp.
BCTX
$3.20
$0.0150.47%
NASDAQ
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -22.02% | -19.09% | -21.92% | 3.07% | 5.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.86% | 13.68% | 43.22% | 69.55% | 64.78% |
| Operating Income | 13.86% | -13.68% | -43.22% | -69.55% | -64.78% |
| Income Before Tax | 7.61% | -26.31% | 75.71% | 66.72% | 45.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 7.61% | -26.31% | 75.71% | 66.72% | 45.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 60.49% | 191.57% | -- | -- | -- |
| Net Income | 8.05% | -25.77% | 76.40% | 67.30% | 46.25% |
| EBIT | 13.86% | -13.68% | -43.22% | -69.55% | -64.78% |
| EBITDA | 14.23% | -13.34% | -42.95% | -69.60% | -64.83% |
| EPS Basic | 58.21% | -3.22% | 77.63% | 68.20% | 47.40% |
| Normalized Basic EPS | 58.47% | -2.93% | 78.02% | 68.53% | 47.60% |
| EPS Diluted | 79.77% | 48.83% | 11.27% | -4.68% | -9.90% |
| Normalized Diluted EPS | 59.27% | -1.08% | 76.82% | 67.21% | 46.57% |
| Average Basic Shares Outstanding | 59.28% | 21.51% | 5.35% | 2.89% | 2.41% |
| Average Diluted Shares Outstanding | 57.56% | 20.18% | 6.46% | 4.01% | 3.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |